Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1

Phase 1

Completed

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: Part A, Reference (D635 10/500mg, Astrazeneca)
Drug: Part B, Reference (D635 10/500mg, Astrazeneca)

First Posted Date: 2019-11-07

Last Posted Date: 2019-11-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 58

Registration Number: NCT04156685

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Seongbuk-Gu, Korea, Republic of

Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients.

Phase 4

Conditions: Kidney Transplant

Interventions: Drug: tacrolimus capsules
Drug: tacrolimus tablet

First Posted Date: 2019-09-25

Last Posted Date: 2020-01-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 128

Registration Number: NCT04102943

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)

Phase 1

Completed

Conditions: Cardiovascular Diseases

Interventions: Drug: Reference drug
Drug: Test drug

First Posted Date: 2019-09-10

Last Posted Date: 2020-02-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 16

Registration Number: NCT04083872

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)

Phase 1

Completed

Conditions: Cardiovascular Diseases

Interventions: Drug: Reference drug
Drug: Test drug 1
Drug: Test drug 2

First Posted Date: 2019-09-10

Last Posted Date: 2020-02-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT04083846

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers

Phase 1

Completed

Conditions: Cardiovascular Diseases

Interventions: Drug: Reference drug
Drug: Test drug

First Posted Date: 2019-09-03

Last Posted Date: 2020-02-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 52

Registration Number: NCT04075643

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Efficacy and Safety of Once-Daily Tacrolimus in Liver Transplant Recipients (SOUL)

Phase 4

Conditions: Liver Transplant

Interventions: Drug: Conversion to Once-daily Tacrolimus

First Posted Date: 2019-08-28

Last Posted Date: 2019-08-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 146

Registration Number: NCT04069065

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Clinical Study to Compare the Safety and Pharmacokinetics of CKD-320 and D012

Phase 1

Conditions: Hypertension

Interventions: Drug: CKD-320, D012

First Posted Date: 2019-07-29

Last Posted Date: 2019-07-29

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 42

Registration Number: NCT04035538

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers

Phase 1

Completed

Conditions: Hypertension
Dyslipidemias

Interventions: Drug: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
Drug: CKD-333 16/10/40mg formulation 1 Tab. 1T
Drug: CKD-333 16/10/40mg formulation 2 Tab. 1T

First Posted Date: 2019-07-15

Last Posted Date: 2020-01-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT04019743

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, South Korea, Korea, Republic of

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation

Phase 3

Conditions: Atrial Fibrillation

Interventions: Drug: CKD-825
Drug: Placebo oral capsule

First Posted Date: 2019-05-15

Last Posted Date: 2019-05-15

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 162

Registration Number: NCT03950843

Locations: 🇰🇷
Jong-ll, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg

Phase 4

Completed

Conditions: Non-erosive Reflux Disease(NERD)

Interventions: Drug: EsoDuo Tab. 20/800mg

First Posted Date: 2019-04-26

Last Posted Date: 2019-12-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 379

Registration Number: NCT03928470

Locations: 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷
Hallym University Chuncheon Seonsim Hospital, Chuncheon, Korea, Republic of

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy